The easiest way to quickly identify novel DUB inhibitors
Screen your compounds across any or all of the 41 individual DUB targets on our panel of enzymes representative of the entire human DUB superfamily.
Alternatively, access our novel compound library of DUB inhibitors, DUBtarget-001. We’ve screened our library through the entire DUBprofiler panel and identified novel hit compounds across the panel. Those data are immediately available to support your DUB focused projects.
DUBprofiler is one of our standard services designed to help you quickly identify DUB (deubiquitylase) inhibitors. Our service is available in a range of different formats:
DUBprofiler SPT for single-point analysis
DUBprofiler IC50 for IC50 determinations
DUBprofiler HT for screening larger numbers of compounds
- As part of this service we can offer high precision and accuracy with ultra-low volume compound dispensing (down to 2.5nl) to enable addition of the assay reagents directly to the compound in 100% DMSO. This is particularly suited to screens where compound solubility and availability is a concern.
The key features of our DUBprofiler service.
DUBprofiler is:
Comprehensive – ability to screen across any or all of the 41 individual DUB targets on our panel representative of the entire DUB family
Robust – ubiquitin-rhodamine(110)-glycine substrate based-assay with multiple controls
Flexible – screen at single concentrations (SPT) or determine IC50 values using standard 8-point half-log concentration-effect curves (IC50)
Scalable – screen any combination of compound(s) vs. DUB
Efficient – simple service procedure using electronic submission forms (supplied on request)
Fast – rapid screening cycles
The process
Contact us and let us know what type of screen you require (SPT, IC50 or HT)
We’ll send you an electronic submission form that lets you select the compound-DUB combination you require. We’ll also send you a set of barcoded tubes for submission of your compounds
Our submission forms also allow you to generate as many quotations as you like based on different combinations of compound numbers and DUBs
Once you’ve finalised your study design, email us the submission form and send us your compounds
Once we’ve received the compounds we’ll immediately schedule them for screening and keep you updated on project progress
Once complete we’ll send you a fully annotated data report and arrange a post project meeting to answer any questions you might have
bio-equip.cn
Ubiquigent Limited is a specialist developer and supplier of Drug Discovery Services, high quality Research Tools and Chemistry to the life science research community worldwide.
Ubiquigent’s scientific and business interests have a clear focus; namely the ubiquitin, ubiquitin-like, and integrated signalling systems.
The Company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery and pharmaceutical and biotechnology company scientists exploring the potential of ubiquitin cascade-focused drug discovery.
Ubiquigent benefits from high calibre backing including from private US investors, the UK Medical Research Council, and the University of Dundee. The Company’s headquarters and laboratory operations are based in the UK and are located in a state-of-the-art facility adjacent to the MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee (both founded by Professor Sir Philip Cohen). In addition to Ubiquigent’s own facilities and capabilities, such proximity provides ready access to a huge range of additional scientific expertise (1,000+ life-science researchers on site), technological competencies, and assay and analytical platforms.
Ubiquigent staff have a wealth of scientific experience, technological competencies and commercial expertise, gained from within academia, the life science research reagents and services sector, and the pharmaceutical industry, that enables the Company to offer a level of understanding and service to its customers and clients worldwide that few companies may match.